[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv---anogenital-human-papilloma-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv---anogenital-human-papilloma-virus-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100651238","comparative-self-collection-for-cervical-cancer-screening-pivotal-study-100651238",false,"NCT07758140","Comparative Self-collection for Cervical Cancer Screening Pivotal Study","MIA-COMP Pivotal Study: COMParative Self-Collection for Cervical Cancer Screening","MIA-COMP","Inclusion Criteria:\n\nGroup 1: General Population Group\n\n1. Participants are 25 to 65 years of age and willing to provide informed consent.\n2. Participants have an intact cervix.\n\nGroup 2: Enriched Population Group\n\n1. Participants are 25 to 65 years of age and willing to provide informed consent.\n2. Participants have an intact cervix.\n3. One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and\u002For presenting for colposcopy\u002FLEEP\u002Fexcisional intervention.\n\nExclusion Criteria:\n\nApply to all groups:\n\n1. Impaired decision-making capacity or inability to provide informed consent.\n2. History of partial or total hysterectomy, including removal of the cervix.\n3. Cervical tissue alteration or surgery within 5 months prior (conization, LEEP, laser ablation, or cryotherapy).\n4. Current pregnancy (based on self-reporting).\n5. Active menstruation at time of specimen collection.\n6. Vaginal bleeding within 48 hours.\n7. Have had sex or used tampons, creams, or other vaginal products in the last 48 hours.\n8. Participation in another clinical study that, in the investigator's opinion, would interfere with the results of this study.\n9. Any medical reason that, in the investigator's opinion, would disqualify the participant for a routine pelvic exam with cervical sample collection.",true,"FEMALE","25 Years","65 Years",{"count":22,"type":23},260,"ESTIMATED","INTERVENTIONAL",[26],"NA","To evaluate whether individuals drawn from the intended use population can successfully interpret and follow the IFU for the Mia by XytoTest self-collection device and perform a vaginal sample collection yielding sufficient cellular material for primary hrHPV screening.\n\nTo assess the clinical performance of Mia self-collected vaginal specimens by evaluating agreement with paired clinician-collected cervical specimens for the detection of high-risk HPV, when both specimen types are analyzed using the cobas HPV Test (Roche Molecular Systems). Residual samples may be used to determine adequacy for additional assays that require vaginal and\u002For cervical specimens (such as mRNA E6 and E7 Biomarker Test, dual stain cytology).",[29,30],"HPV","HPV - Anogenital Human Papilloma Virus Infection",[32,33],"hrHPV","cobas HPV test","RECRUITING","2026-08-06",{"date":37,"type":38},"2026-08-11","ACTUAL",{"date":40,"type":38},"2026-07-09",{"date":42,"type":23},"2026-09",{"name":44,"class":45},"Mel Mont Medical","INDUSTRY",11,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100627597","the-effect-of-the-health-belief-model-based-education-given-to-mothers-of-children-aged-9-15-on-hpv-knowledge-level-and-child-vaccination-100627597","NCT07450703","The Effect of the Health Belief Model-Based Education Given to Mothers of Children Aged 9-15 on HPV Knowledge Level and Child Vaccination","The Effect of Health Belief Model-Based Education on Mothers of Children Aged 9-15 Years: Impact on HPV Knowledge Level and Child Vaccination","Inclusion Criteria:\n\n* Literate and able to understand and speak Turkish\n* Mother of a child aged 9-15 years\n* Did not receive any HPV-related education in the past 6 months\n* Has not had HPV vaccination previously\n* Willing to participate voluntarily\n\nExclusion Criteria:\n\n* Presence of serious physical or cognitive impairment preventing participation\n* Refusal to provide informed consent\n* Already vaccinated against HPV\n* Already received HPV-related education within the last 6 months",{"count":55,"type":23},100,[26],"This study aims to examine the effects of education provided to mothers of children aged 9-15 within the framework of the Health Belief Model on mothers' knowledge, attitudes, and behaviors about Human Papillomavirus (HPV), and their willingness to have their children vaccinated against HPV. The study, designed with a randomized controlled experimental design, will be conducted at three different Family Health Centers in Gaziantep and will consist of both experimental and control groups. Mothers in the experimental group will receive a three-session visually supported education program prepared by Yıldız USCA, while the control group will receive routine information using HPV brochures from the Ministry of Health. Data collection tools include a personal information form, an HPV knowledge scale, and an HPV Health Belief Model scale.",[59,30,60],"Cancer , Healthy","Health Belief Model",[62,63,64],"HUMAN PAPİLLOMA VIRUS","WOMEN HEALTH","VACCINE EDUCATİON","NOT_YET_RECRUITING","2026-03-01",{"date":68,"type":38},"2026-03-05",{"date":70,"type":23},"2026-04-01",{"date":72,"type":23},"2026-12-01",{"name":74,"class":75},"University of Gaziantep","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":19,"maxAge":20,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100617558","effect-of-a-dietary-supplement-containing-egcg-folic-acid-vitamin-b12-and-hyaluronic-acid-in-supporting-male-genital-balance-in-subjects-exposed-to-hpv-risk-100617558","NCT07320183","Effect of a Dietary Supplement Containing EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid in Supporting Male Genital Balance in Subjects Exposed to HPV Risk","PERVI-M","Inclusion Criteria:\n\n* Signed informed consent\n* Couple seeking pregnancy\n* Male partner aged 25-65 years\n* HPV DNA test indicating active HPV infection in the male partner\n* HPV DNA test indicating negativity for HPV infection in the female partner\n\nExclusion Criteria:\n\n* Concomitant diseases causing immunosuppression\n* Treatment with immunomodulatory therapies\n* Use of EGCG or other green tea extracts","ALL",{"count":85,"type":23},96,[26],"Pilot interventional study aimed at evaluating the effect of a dietary supplement containing EGCG, vitamin B12, hyaluronic acid, and folic acid on the maintenance of physiological balance of the genital mucosa and natural defenses of the male genital tract, as well as on the maintenance of HPV-DNA test negativity, in subjects undergoing natural procreation pathways. The study will also assess the potential support of sperm parameters, reproductive well-being of the couple, and the reduction of risk factors associated with HPV transmission to the female partner. A total of 34 HPV-positive couples attending the Istituto Scientifico Internazionale \"Paolo VI\" of the Policlinico A. Gemelli will be enrolled and randomized into two groups: 17 couples in the intervention group, in which the male partner will receive the supplement (EGCG 200 mg, vitamin B12 1 mg, hyaluronic acid 50 mg, folic acid 400 μg, one tablet daily for 6 months), and 17 couples in the control group with no supplementation.",[30,89],"Infertilities",[91],"HPV- infertility","2026-01-07",{"date":94,"type":38},"2026-01-08",{"date":66,"type":23},{"date":97,"type":23},"2028-03",{"name":99,"class":75},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]